FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2314294082> ?p ?o ?g. }

• W2314294082 endingPage "S147" @default.
• W2314294082 startingPage "S146" @default.
• W2314294082 abstract "Plerixafor is a reversible CXCR4 antagonist that has been approved by the food and drug administration for autologous hematopoietic stem cell mobilization in patients with multiple myeloma and non-hodgkin’s lymphoma. Patients mobilized with Plerixafor were shown to have a higher proportion of primitive stem cells (CD34+/CD133+/CD38-), CD4+ T cells and Natural killer cells (CD3-/CD16+/CD56+) in the graft composition when compared to patients mobilized with chemotherapy plus G-CSF alone. We investigated the effect of Plerixafor on immune reconstitution at thirty and sixty days post autologous stem cell transplantation. Patients eligible for autologous stem cell transplantation were enrolled on a single arm prospective immune reconstitution trial. A complete blood count, differential and lymphocyte flow cytometry panel (T cell, NK cell and B cell markers) was checked on Days 30 and 60 post autologous transplantation. Stem cell mobilization was carried per our institutional standards. All patients received subcutaneous G-CSF at a dose of 10 μg per kilogram body weight for four consecutive days. On Day4, patient with a peripheral CD34 count of ≤20/μl received plerixafor 0.24mg/kg. Collection was started on day 5 and continued till collection goal was reached or patient failed to get the minimal cell dose after 4 consecutive days of pheresis. 49 patients were enrolled during the period from September 2010 till May 2012. Median age at time of transplantation was 54 years (range 21;72 years). 35 patients had multiple myeloma and 14 had non-Hodgkin’s lymphoma. 16 patients received GCSF alone (group A) and 33 had plerixafor plus GCSF (group B) for mobilization. All patients achieved the minimum target of CD34 collection. The mean number of collection days was 1.9 and 1.4 days (p=0.05) with a total collection dose of 7.76 and 7.61 CD34 x106/Kg for groups A and B respectively. The percentage proportion of CD34 in the aphaeresis product was 0.73% and 0.75% (p=0.9) for group A and B. Total infused CD34 dose was similar in both groups (4.88 and 4.56 CD34x106/kg) with time to engraftment of 11.68 vs 11.69 days for neutrophils and 20.62 vs 21.39 for platelets in groups A and B respectively. There was no difference between day 30 absolute lymphocyte count (1.09 vs 1.44 x103/mm3 p=0.18); Absolute NK cell (0.31 vs 0.35 x103/μl; p=0.51); absolute T cell count (0.71 vs 0.96 x103/μl p=0.33) and absolute neutrophil count (2.98 vs 2.63 x103/mm3 p=0.37). The cell count recovery was also not significantly different when analyzed per disease (myeloma or non-Hodgkin’s lymphoma) and at day 60. Our study shows that patient mobilized with plerixafor and G-CSF have similar immune reconstitution at 30 and 60 days post autologous transplantation compared to patients mobilized with G-CSF alone." @default.
• W2314294082 created "2016-06-24" @default.
• W2314294082 creator A5004066032 @default.
• W2314294082 creator A5043845631 @default.
• W2314294082 creator A5061091483 @default.
• W2314294082 creator A5081939031 @default.
• W2314294082 date "2014-02-01" @default.
• W2314294082 modified "2023-10-18" @default.
• W2314294082 title "Effect of Mobilization Method on Immune Reconstitution Post High Dose Chemotherapy and Autologous Stem Cell Transplantation" @default.
• W2314294082 doi "https://doi.org/10.1016/j.bbmt.2013.12.226" @default.
• W2314294082 hasPublicationYear "2014" @default.
• W2314294082 type Work @default.
• W2314294082 sameAs 2314294082 @default.
• W2314294082 citedByCount "0" @default.
• W2314294082 crossrefType "journal-article" @default.
• W2314294082 hasAuthorship W2314294082A5004066032 @default.
• W2314294082 hasAuthorship W2314294082A5043845631 @default.
• W2314294082 hasAuthorship W2314294082A5061091483 @default.
• W2314294082 hasAuthorship W2314294082A5081939031 @default.
• W2314294082 hasBestOaLocation W23142940821 @default.
• W2314294082 hasConcept C10205521 @default.
• W2314294082 hasConcept C126322002 @default.
• W2314294082 hasConcept C129470790 @default.
• W2314294082 hasConcept C13373296 @default.
• W2314294082 hasConcept C141071460 @default.
• W2314294082 hasConcept C203014093 @default.
• W2314294082 hasConcept C2776364478 @default.
• W2314294082 hasConcept C2776694085 @default.
• W2314294082 hasConcept C2777408962 @default.
• W2314294082 hasConcept C2778828106 @default.
• W2314294082 hasConcept C2779050716 @default.
• W2314294082 hasConcept C2779338263 @default.
• W2314294082 hasConcept C2779695342 @default.
• W2314294082 hasConcept C28328180 @default.
• W2314294082 hasConcept C2911091166 @default.
• W2314294082 hasConcept C54355233 @default.
• W2314294082 hasConcept C71924100 @default.
• W2314294082 hasConcept C86803240 @default.
• W2314294082 hasConcept C8891405 @default.
• W2314294082 hasConcept C90924648 @default.
• W2314294082 hasConceptScore W2314294082C10205521 @default.
• W2314294082 hasConceptScore W2314294082C126322002 @default.
• W2314294082 hasConceptScore W2314294082C129470790 @default.
• W2314294082 hasConceptScore W2314294082C13373296 @default.
• W2314294082 hasConceptScore W2314294082C141071460 @default.
• W2314294082 hasConceptScore W2314294082C203014093 @default.
• W2314294082 hasConceptScore W2314294082C2776364478 @default.
• W2314294082 hasConceptScore W2314294082C2776694085 @default.
• W2314294082 hasConceptScore W2314294082C2777408962 @default.
• W2314294082 hasConceptScore W2314294082C2778828106 @default.
• W2314294082 hasConceptScore W2314294082C2779050716 @default.
• W2314294082 hasConceptScore W2314294082C2779338263 @default.
• W2314294082 hasConceptScore W2314294082C2779695342 @default.
• W2314294082 hasConceptScore W2314294082C28328180 @default.
• W2314294082 hasConceptScore W2314294082C2911091166 @default.
• W2314294082 hasConceptScore W2314294082C54355233 @default.
• W2314294082 hasConceptScore W2314294082C71924100 @default.
• W2314294082 hasConceptScore W2314294082C86803240 @default.
• W2314294082 hasConceptScore W2314294082C8891405 @default.
• W2314294082 hasConceptScore W2314294082C90924648 @default.
• W2314294082 hasIssue "2" @default.
• W2314294082 hasLocation W23142940821 @default.
• W2314294082 hasOpenAccess W2314294082 @default.
• W2314294082 hasPrimaryLocation W23142940821 @default.
• W2314294082 hasRelatedWork W134016865 @default.
• W2314294082 hasRelatedWork W1572109053 @default.
• W2314294082 hasRelatedWork W1818467446 @default.
• W2314294082 hasRelatedWork W1895328588 @default.
• W2314294082 hasRelatedWork W2016206185 @default.
• W2314294082 hasRelatedWork W2998580418 @default.
• W2314294082 hasRelatedWork W3031522679 @default.
• W2314294082 hasRelatedWork W3128368052 @default.
• W2314294082 hasRelatedWork W4310797259 @default.
• W2314294082 hasRelatedWork W4311667880 @default.
• W2314294082 hasVolume "20" @default.
• W2314294082 isParatext "false" @default.
• W2314294082 isRetracted "false" @default.
• W2314294082 magId "2314294082" @default.
• W2314294082 workType "article" @default.